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1. Introduction 
In sub-Saharan Africa neurocysticercosis (NCC), which represents the infection of a human 
brain with the larva (=cysticercus) of the pork tapeworm (=Taenia solium), and epilepsy due 
to various causes are among the most frequent neurological disorders/syndromes. To date, 
NCC in the context of sub-Saharan Africa has not attracted much attention despite the fact 
that the prevalence rates of human and porcine cysticercosis seem to increase and both 
diseases are treatable. Epilepsy represents the most common neurological disorder in many 
parts of sub-Saharan Africa and NCC seems to be a major cause of it in Taenia solium 
cysticercosis endemic areas. Diagnosing NCC among people with epilepsy is vital as this not 
only prevents further morbidity and mortality through potential aggravation of the disease, 
but also leads to a different treatment approach: from a mere symptomatic treatment with 
administration of antiepileptic medication only to a curative approach, assuming that once 
the parasite has been cleared epileptic seizures will cease. However, in the diagnosis and 
treatment of NCC neuroimaging plays a crucial role and this has to be considered when 
dealing with affected individuals form resource-poor settings, where neuroimaging is not 
available. Therefore special diagnostic and therapeutic guidelines for sub-Saharan Africa 
have to be developed, but so far national and international stakeholders have not taken this 
into consideration. This chapter aims at raising awareness of both NCC and epilepsy in sub-
Saharan African, appealing to the international community to consider NCC in resource-
poor settings as a separate entity regarding its diagnostic and therapeutic approach with the 
need for clearly defined guidelines in the described context. 
1.1. Definition of epilepsy and acute symptomatic epileptic seizures 
A condition characterized by recurrent (two or more) afebrile epileptic seizures that is 
unprovoked by any immediate identified cause and thus is not due to an acute intracranial 
or extracranial condition is termed epilepsy [1]. A person who has had a seizure within the 
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last five years and those on anticonvulsant medication are considered to have “active 
epilepsy” [1,2]. The definition of active epilepsy does not have implications on starting 
antiepileptic treatment. Some African researchers suggest starting treatment if the last 
seizure was within the previous year [3]. We advocate for a more flexible initiation of 
antiepileptic treatment. Treatment of epilepsy always has to be considered on a 
multifactorial basis and includes the risk of recurrence based on seizure pathology (e.g., 
generalized versus focal epilepsy), seizure frequency, associated disease and available 
antiepileptic treatment, among others. 
Epileptic seizures that are based on intracranial pathologies, such as parasitic disease, 
cerebrovascular accidents or trauma, and stop after the underlying cause, e.g. the associated 
oedema, has resolved, are called acute symptomatic epileptic seizures and have to be 
differentiated from epileptic seizures in the context of “chronic” epilepsy. In “chronic epilepsy” 
brain lesions may still be present, but they belong to the entity of neurological sequelae such as 
calcifications after parasitic diseases or chronic lesions in the context of cerebrovascular 
accidents or trauma, among others. These lesions most likely will not undergo further changes 
and therefore the “chronic” epilepsy type is treated symptomatically with antiepileptic drugs. 
In acute symptomatic epileptic seizures treatment of the primary cause is mandatory, if 
possible, but antiepileptic drugs are often added. After the acute phase withdrawal of 
antiepileptic treatment is desirable, but has to be decided on a case-to-case basis. 
1.2. Prevalence of epilepsy in sub-Saharan Africa 
In sub-Saharan Africa, epilepsy is among the most common neurological disorders. Its 
devastating impact on individuals suffering from it as well as on affected African 
communities was described as early as 1960 in Mahenge, southern Tanzania [4]. These early 
anecdotal reports were corroborated by a large-scale hospital-based study in Nigeria in the 
1970s [5]. Since then, prevalence data on epilepsy have been collected in community-based 
studies throughout Africa with varying results depending on the study population and the 
methodologies used (mainly on active epilepsy), ranging from 5.2-74.4/1000 with a median 
of 15/1000 inhabitants [6,7]. This is compared to high-income countries where the prevalence 
of active epilepsy is estimated to be about 4-8/1000 inhabitants [8]. Interestingly, hotspots of 
highly prevalent epilepsy have been reported in various African countries such as Benin, the 
Ivory Coast, Cameroon, Nigeria, Senegal and Tanzania [6,9]. Causes for these high 
prevalence rates have so far not been identified, but they are deemed to be partly genetic in 
nature, most likely with a consistent environmental factor that affects genetically 
predisposed individuals [6].  
Our own data from a hospital-based study on neurological disorders in northern Tanzania 
show epileptic seizures to be the most prevalent neurological disorder [10,11]. Of the 740 
patients with neurological symptoms/signs, 272 (36.8%) had at least one epileptic seizure 
during their stay at the hospital or immediately before admission to the hospital. Febrile 
seizures (82/272; 30.2%) accounted for the majority of epileptic seizures. This was followed 
by symptomatic epileptic seizures (72/272; 26.5%), which were mainly due to cerebral 
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infections, then epilepsy (65/272; 23.9%) as defined by the International League Against 
Epilepsy [1]. Assumed symptomatic seizures without an obvious cause that did not meet the 
criteria of epilepsy occurred in 15.4% (42/272) and pseudoseizures were witnessed in 4.0% 
(11/272). The mortality rate of the patients with epileptic seizures was high with 18.8% 
(51/272). Peak mortality rates were found in people with symptomatic disease and those 
with assumed symptomatic epileptic seizures, at 38.9% (28/72) and 31.0% (13/42), 
respectively. These results clearly show where the burden of neurological disorders in sub-
Saharan Africa, in our case northern Tanzania, lies and have implications for the objective of 
delivering appropriate care for patients suffering from epileptic seizures [10].  
The high prevalence rates of epileptic seizures/epilepsy found in the above hospital-based 
study were also confirmed in a community-based setting. Of the 7399 people who were 
visited in a community-based study in the same area the above hospital-based study was 
conducted 83 people were diagnosed with epilepsy and of those 64 had active epilepsy (last 
seizure within the last 5 years; [12]). The point prevalence of epilepsy within the study 
population of 7399 people was 11.2/1000 (95% CI 8.9-13.9/1000) with an age-adjusted 
prevalence of 13.2/1000. The prevalence of active epilepsy was 8.7/1000 (95% CI 6.7-
11.0/1000) with an age-adjusted rate of 9.1/1000. The majority of patients suffered from 
generalized epilepsies. Not surprisingly, three quarters of the people with epilepsy had 
never accessed any health facilities [12].  
Our findings confirm high prevalence rates of epileptic seizures/epilepsy in the hospital and 
the community, which agrees with the results of previous epidemiological studies of epilepsy 
in sub-Saharan Africa [5,6,9,13-19]. Most studies conducted in parts of Africa and Latin 
America indicate higher prevalence rates of epilepsy than have been found in high-income 
countries, but these prevalence rates can vary within a single country, as shown in Benin, the 
Ivory Coast, Senegal and Tanzania [6,9,19]. In a recent large-scale study from Kenya, it was 
shown that the active prevalence was only 4.5/1000, and therefore in the range of prevalence 
rates of high-income countries, with a high heterogeneity of prevalence rates across different 
areas ranging from below 1.0/1000 to 12.9/1000 [3]. Active epilepsy was defined as at least one 
seizure during the last year (the usual definition is one seizure during the last five years; see 
1.1.) which may account for the lower prevalence rate found.  
1.3. Classification of epileptic seizures/epilepsy in resource-poor settings 
Classifying epileptic seizures/epilepsy in resource-poor countries can be challenging, 
bearing in mind that the availability of diagnostic tools such as appropriate serological 
investigations, electroencephalography and neuroimaging can be scare or, especially in rural 
Africa, absent altogether. Whether the seizures reported in rural Africa are primarily 
generalized or focal in nature is still a matter of debate and depends upon the setting and 
methodology used (e.g. hospital-based versus community-based), the country of 
investigation, the questionnaires used (different sensitivities and specificities) and the 
diagnostic tools available [6]. While members of the International League Against Epilepsy 
have developed consensus papers on the best classification of epileptic seizures [20] and 
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epilepsies [21,22] that are considered international standards, they mainly refer to high-
income countries, which only include 20% of all people with epilepsy worldwide [23,24]. In 
contrast, appropriate classification systems for epileptic seizures/epilepsy in low-income 
countries seem to be virtually absent. Seizure semiology, the description of which can be 
incomplete due to language and sociocultural barriers, and important seizure related issues 
such as possible aetiologies and concomitant diseases (e.g. perinatal neurological sequelae) 
are relevant for the classification of epileptic seizures/epilepsy in these countries and should 
form parts of an adapted classification system. The growing relevance of global neurology 
together with the already substantial burden of epileptic seizures/epilepsy in sub-Saharan 
Africa calls for an expert-led committee to decide on an appropriate classification system for 
epileptic seizures/epilepsy for clinical use in low-resource countries. 
We suggest a classification system that is based on clinical grounds alone, and mainly refers 
to the description of seizures provided by the patients and their relatives along with 
relevant information from past medical histories, birth and family histories and a thorough 
neurological examination. Electroencephalography and neuroimaging are not usually at 
hand in resource-poor settings and therefore are not included in the classification system. 
The classification system suggested is based on the classification of epileptic seizures and 
epilepsy as stipulated by the International League Against Epilepsy [1,20-22]. Based on our 
experience while working in northern Tanzania we identified four main categories of 
epileptic seizures/epilepsy that have different needs for further investigation, treatment and 
follow-up, showing variable prognoses ([25,26]; Figure 1).  
Generalized types of seizure: 
1. Generalized seizures within a specific age range: primary generalized seizures that start 
within a specific age group (mainly between 6 and 25 years). Seizures in this group can 
also be termed idiopathic generalized epilepsy. 
Cause: none obvious 
Prognosis: good 
Investigations: keep to a minimum 
2. Generalized seizures outside a specific age range: primary generalized seizures that start 
outside the specific age range of most of the idiopathic generalized epilepsies where no 
symptoms/signs on clinical examination suggest a secondary cause. 
Cause: none obvious, seizures may be “cryptogenic”. 
Prognosis: variable 
Investigations: further investigations necessary (electroencephalography, neuroimaging) 
Partial types of seizure that clinically appear as generalized seizures: 
3. Generalized seizures with diffuse brain damage: secondary generalized seizures that start in 
a generalized way, but diffuse brain damage with mental retardation is obvious. The 
large majority of patients are children. 
Cause: mostly known (e.g. birth defect) 
Prognosis: variable 
Investigations: keep to a minimum 
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4. Generalized seizures with focal signs: secondary generalized seizures with a focal start, 
clear unilateral seizures or focal neurological signs upon examination but without signs 
of diffuse brain damage. 
Cause: may become obvious upon further investigation 
Prognosis: depends on the underlying cause 
Investigations: further investigations necessary (electroencephalography, 
neuroimaging) 
 
Figure 1. Algorithm on how to classify people with epilepsy in resource-poor countries regarding 
diagnostic and therapeutic implications. Primary generalised seizures are split according to the age of 
onset (see text); these two groups have a different diagnostic and therapeutic approach. Patients with 
primary generalised seizures that start outside 6-25 years are more likely to have cerebral lesions than 
patients whose epilepsies start within 6-25 years where idiopathic epilepsy prevails, and therefore need 
further investigation. In people with epilepsy and diffuse brain damage, diagnostic tests are rarely 
needed as the extent of the cerebral sequelae is known and the condition is not progressive. In contrast, 
in people with epilepsy who show focal signs without diffuse brain damage, further diagnostic steps 
are essential in order to identify the underlying, potentially treatable cause. In all four groups, treatment 
depends mainly on the age of the patient, seizure activity, seizure frequency, the presence of mental 
handicap and the presence of focal neurological signs, bearing in mind that the choice of antiepileptic 
medication is limited. CBZ = carbamazepine, PHT = phenytoin, PHB = phenobarbitone. 
We opted for a simply structured, easy-to-understand classification system that mainly 
consists of the four groups of epileptic seizures/epilepsy described above based on seizure 
description, clinical information and a physical examination (Figure 1). Our classification 
shares many similarities with the International League Against Epilepsy classifications [1, 
20-22], especially the International Classification of Epileptic Seizures [20], but it has been 
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tailored to fit local circumstances. This was deemed important in order to gain information 
on possible causes, necessary investigations within a resource-poor setting, best antiepileptic 
treatments and prognoses of seizure disorders (Figure 1). 
The “generalized types of seizure” (groups 1 and 2; Figure 1) were divided according to age 
at onset. They presented as classic primary generalized seizures without any suggestion of 
focal neurological signs or focal seizure onset. The subdivision of primary generalized 
seizures into those that start within a specific age range (6-25 years;[27]) and those that start 
outside of this age range was deemed important as the approach used for each is different 
(Figure 1). Idiopathic epilepsy types include distinct seizure syndromes with distinct ages of 
onset, although mainly within the postulated age group of 6-25 years [27-29]. Primary 
generalized seizures outside of this age range, either below about 6 years or above about 25 
years, can still be idiopathic in nature, although seizures caused by brain lesions, especially 
in a resource-poor setting, may prevail. Our hospital-based study showed that symptomatic 
seizures are frequent. When looking at the exact age distribution, 70.8 % (51/72) of the 
patients with symptomatic seizures were aged either below 6 years or above 25 years when 
presenting with symptomatic seizures [10]. Therefore, for people with epilepsy presenting 
with primary generalized seizures that fall into these age groups, further investigations with 
electroencephalography and neuroimaging seem to be important (Figure 1). 
The “partial types of seizure with the clinical appearance of generalized seizures” (groups 3 
and 4; Figure 1) were divided according to the extent of brain damage associated with the 
seizures. Mental retardation and intellectual decline due to serious brain disorders in 
children of resource-poor countries are much more frequent compared to resource-rich 
countries [30,31]. These are often associated with epileptic seizures that are difficult to treat 
and have an unfavourable prognosis [32]. Thus, this group of people with epilepsy deserves 
special attention, and therefore has been summarized as a separate group (group 3). In 
children with more widespread brain damage, antiepileptic drugs with sedative effects such 
as phenobarbitone could further hamper intellectual development. Often, additional 
diagnostic tests do not add to the management of these young patients as the cause of 
cerebral sequelae is known and the condition is not progressive (Figure 1). “Over-
diagnosing” patients in this context can cause unnecessary financial burden to the families. 
Epilepsy in resource-poor countries is often associated with brain lesions of various origins, 
with infection and trauma being the most important causes in this setting [2, 33]. These 
patients can show focal neurological signs and/or present with clinically obvious secondary 
generalized seizures, but, in contrast to group 3, they do not show signs of more widespread 
brain damage. Often, a patient is previously healthy before a special event precedes the 
onset of seizures, although this is not mandatory. Further diagnostic procedures in these 
patients are important in order to identify the underlying, potentially treatable cause of the 
epilepsy (Figure 1). 
In summary, we have identified four major groups of epileptic seizures on clinical grounds 
that are relevant to the diagnosis of epilepsy in sub-Saharan Africa. The suggested 
investigations within a resource-poor setting, treatment and prognosis differ between the 
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groups, and a classification of affected patients within the most appropriate group could 
help guide the clinician towards the appropriate management of people with epilepsy 
within a rural African setting. 
1.4. Treatment gap of epilepsy in sub-Saharan Africa 
In many African countries, epileptic seizures/epilepsy represent a tremendous socio-economic 
burden, partly due to the chronicity of the disease, and therefore not only have repercussions 
on individuals but also on their families and the community they live in. The figures released 
by the WHO are convincing: 50 million people worldwide suffer from epilepsy; 80% of them 
live in resource-poor countries [23] and of these up to 90% are untreated or treated 
insufficiently [34]. Newer figures indicate that 63 million people live with epilepsy in low- and 
middle-income countries [35]. This 90% treatment gap was corroborated by studies from 
northern and southern Tanzania showing that 76% and 95% of people with epilepsy, 
respectively, had not been treated [12,19]. Dramatic global disparities in this treatment gap 
were identified by a systematic review which showed that 75% and fewer than 10% of PWE 
from low-income and high-income countries, respectively, were untreated or insufficiently 
treated for their epilepsy [36]. A recent study from Kenya demonstrated an epilepsy treatment 
gap of 62% using serum antiepileptic drug levels as a measure of compliance and found that 
self-reporting of compliance to antiepileptic medication was very unreliable when compared 
to the serum antiepileptic drug levels [37,38].  
Although access to modern medicine is limited for people with epilepsy who live in sub-
Saharan Africa, traditional medicines are widely used as they represent the only treatments 
that are accessible to most of the affected population. The lack of awareness of local and 
international policy makers, poor infrastructure, long travel distances, the insufficient or 
only intermittent availability of antiepileptic medications, the lack of education among 
people with epilepsy, their families and the communities, the predominance of traditional 
belief systems and the scarcity of trained medical personnel may be responsible for this 
large treatment gap [39,40]. Another important but often neglected cause of this treatment 
gap is social stigma. In many countries of sub-Saharan Africa, epilepsy has mystical 
connotations, which is another reason why the majority of people with epilepsy resort to 
traditional medicines before even considering modern medicine. In many societies, epilepsy 
is viewed as punishment for sins or breaking taboos, a curse, bewitchment or demoniac 
possession, as well as a contagious disease, resulting in the rejection and discrimination of 
affected individuals [41]. A recent study from Zambia showed that people with epilepsy are 
disadvantaged regarding social and economic matters compared to people with other 
chronic diseases without an attached stigma, such as asthma, diabetes mellitus, 
hypertension and rheumatic heart disease [42]. The aforementioned aspects all contribute to 
the fact that the majority of people with epilepsy go untreated. This treatment gap is the 
main cause of individual suffering and the socio-economic burden of the disease, 
necessitating improvements in therapeutic strategies [6,43,44]. A pre-requisite for successful 
treatment also includes a good knowledge of the possible aetiologies of seizure disorders as 
treatment can largely depend on underlying pathologies. 
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1.5. Causes of epileptic seizures/epilepsy in sub-Saharan Africa 
Causes of epileptic seizures/epilepsy are highly variable across different regions of sub-
Saharan Africa and depend on geographical, climatic, political, social and hygienic 
conditions. However, the main and most important causes of epilepsy seem to be very 
similar throughout sub-Saharan Africa and have been studied in great detail, both in 
hospital and community settings, showing that a positive family history (genetic 
predisposition), a past history of febrile convulsions, perinatal neurological disorders, head 
injuries, cerebrovascular accidents and infections of the central nervous system account for 
most cases of epilepsy [6]. Also included are a variety of protozoon (the most important 
being cerebral malaria) and helminthic infections, of which Taenia solium (its larval stage 
causing cysticercosis) has attracted considerable attention in sub-Saharan Africa over the past 
few years. Therefore, epileptic seizures/epilepsy in the context of NCC will be described in 
more detail in the following paragraphs in order to provide adequate information on clinical 
characteristics, diagnosis and treatment in the context of sub-Saharan Africa. 
2. Prevalence of neurocysticercosis in sub-Saharan Africa 
NCC represents the most common helminthic infection of the central nervous system [45] 
and is endemic in most countries of Latin America, Asia and sub-Saharan Africa. NCC is not 
only one of the major causes of acquired epileptic seizures/epilepsy in low-resource countries, 
but it is also of increasing concern in so far non-endemic countries, such as Europe and the 
United States, due to globalization and the migration of infected people [46-50].  
Community-based estimation of the prevalence of NCC is difficult as neuroimaging would 
have to be applied to a large population putting seemingly healthy people at risk of 
radiation and therefore has been performed rarely so far [51]. In contrast, the prevalence of 
human Taenia solium cysticercosis in communities has been assessed as this requires blood 
analysis only. In cysticercosis endemic areas of the Democratic Republic of Congo, Burkina 
Faso and Zambia the prevalence of Taenia solium cysticercosis as measured with an antigen-
ELISA was 22%, 10% and 5.8%, respectively [52-54]. Indirect approaches are used to get an 
impression about the prevalence of people with NCC in a certain population and often 
people suffering from epileptic seizures or epilepsy are included into these studies. The 
prevalence of epilepsy has shown to be high in a Taenia solium cysticercosis endemic area 
from Burkina Faso which found an epilepsy lifetime prevalence of 4.5% [55]. A recent meta-
analysis on the prevalence of NCC in people with epilepsy, including 12 studies mainly 
from Latin America, India and sub-Saharan Africa, found that NCC was the cause of 
epilepsy in almost 30% of people with epilepsy [56].  
If extrapolating the above results to the entire population of sub-Saharan Africa (850 million 
people; [57]) and assuming a prevalence of epilepsy of 4-13/1000 [3,12], approximately 3.4 to 
11.05 million people would suffer from epilepsy. Thirty per cent of it is due to NCC yielding 
1.02-3.32 million people with epilepsy due to NCC in sub-Saharan Africa. Epilepsy makes 
up for approximately 80% of the symptoms in NCC [58] and therefore 1.28-4.15 million 
people would suffer from symptomatic NCC including all neurological signs/symptoms (see 
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2.4.). We also know that symptomatic NCC is only the tip of the iceberg and that the 
majority of people with NCC are asymptomatic. We assume conservatively 50% of all NCC 
cases to be asymptomatic [59]. Therefore the total of all people suffering from NCC in sub-
Saharan Africa would be somewhere between 2.56-8.30 million. These figures would 
however come down if only areas confirmed with endemic Taenia solium cysticercosis would 
be considered. Currently a number of 631 776 908 people has been assumed to live in the 
Taenia solium cysticercosis endemic areas of sub-Saharan Africa (endemic countries: [60]; 
populations in these endemic countries: [61]) yielding an NCC-based epilepsy population of 
0.76-2.46 million and a population suffering from symptomatic NCC of 0.95-3.08 million. 
The same amount of people would suffer from asymptomatic NCC, if assuming that 50% of 
all cases are asymptomatic. 
Latent NCC cases when harbouring Taenia solium cysticerci can become symptomatic at any 
time due to the natural course of disease or in the context of treatment received for intestinal 
parasites [62]. These people are also at risk of developing symptomatic disease through 
mass drug administration for soil-transmitted helminths and schistosomiasis, among others 
[63-66]. Praziquantel and albendazole, two antihelminthic drugs (see 2.6.1.), are at the heart 
of mass drug administration and may be able to convert latent NCC to symptomatic NCC 
by destroying the parasite and potentially provoking brain oedema [65,66]. Anecdotal 
reports of sudden onset of serious neurological signs and/or death after mass drug 
administration have been noted, but to date no large-scale studies on the topic of the side 
effects after mass drug administration in carriers of latent cysticerci have been performed. 
Such studies are desperately needed to evaluate the risk of symptomatic NCC with 
potentially ensuing death in many hundreds of thousands of people in sub-Saharan Africa. 
For more details on the calculation of how many people in sub-Saharan Africa would 
potentially be at risk of developing neurological side effects after mass drug administration 
of praziquantel and albendazole refer to Winkler [67]. 
NCC not only imposes a huge socioeconomic burden onto the health systems of affected 
African nations (see 2.3.), but also indicates that people who potentially could be cured from 
their epilepsy by antihelminthic medication are practically left untreated. Data on sub-
Saharan prevalence rates of NCC in people with epileptic seizures/epilepsy are mainly 
based on serological results and only exist from a few countries with results of over 40% 
(Cameroon) depending on the serological tests used [68-70]. A recent meta-analysis that 
only included African studies showed a significant association between epilepsy and 
cysticercosis with an odds ratio of 3.4 [71]. More details on the prevalence of NCC (serology 
and imaging) are available from South African studies [68], where one study found 50.6% of 
newly diagnosed people with epilepsy showing lesions of NCC on neuroimaging [72]. The 
only neuroimaging-based study in sub-Saharan Africa outside South Africa was performed 
from our own group. Definite NCC lesions on computed tomography (CT) were 
demonstrated in 2.4% (5/212) of people with epilepsy, lesions highly suggestive of NCC 
were present in 11.3% (24/212) and lesions compatible with NCC were found in 4.2% (9/212). 
The NCC lesions were significantly more frequent in people with epilepsy compared to the 
controls [73].  
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Although it was clearly demonstrated that NCC in people with epilepsy from sub-Saharan 
Africa is prevalent, there is still some controversy regarding the manifestation of NCC in 
different age groups. In a recently conducted study, there was a trend of people with 
epilepsy and NCC being older and having their first seizure later compared to people with 
epilepsy without NCC [74]. Other studies also report that NCC is the cause of late-onset 
epilepsy [75-78]. A possible reason might be that older people with epilepsy are more 
susceptible to the infection. However, especially the calcified stage of NCC was found to be 
more common in younger people with epilepsy, whereas cysts were found to be more 
common in older people with epilepsy [73,74]. This may be explained by a different 
immunoresponse to the infection with age. The age of first manifestation of NCC seems 
however difficult to obtain, especially in sub-Saharan Africa, as children are often excluded 
from neuroimaging studies for obvious ethical reasons, although several reports have 
demonstrated the presence of NCC among children [79-83]. 
2.1. Neurocysticercosis in people with HIV/AIDS 
Most NCC endemic areas are also endemic for HIV/AIDS and interaction of the two diseases, 
as known for HIV/AIDS and malaria and HIV/AIDS and tuberculosis, would seem plausible. 
Indeed, acceleration of the clinical course of HIV/AIDS in patients co-infected with Taenia 
solium cysticerci has been suggested based on the manipulation of the immune system by the 
parasite [84,85]. In South Africa, NCC has been described as one of the most important focal 
brain lesion in people with HIV/AIDS with neurological signs depending on the location of the 
lesion. Interestingly intraventricular NCC seems to be especially common in patients with 
HIV/AIDS from South Africa presenting with epileptic seizures and signs of increased 
intracranial pressure, among others. Treatment with ventriculo-peritoneal shunts carries a 
bleak prognosis, whereas antihelminthic medication together with steroids shows a better 
outcome in these patients. These reports from South Africa are fairly worrying and repeated 
regular treatment with short courses of praziquantel together with steroids have been 
advocated for HIV/AIDS patients from highly endemic areas to reduce the rate of re-infection 
which may accelerate the course of disease, if left untreated [84]. However, to date no 
systematic studies on co-infection with Taenia solium cysticerci and HIV have been conducted 
in sub-Saharan Africa. Observations from South Africa indicate that co-infection is high 
[84,85]. Conversely, studies from India and Mexico have shown that seroprevalence of Taenia 
solium cysticercosis in patients with HIV/AIDS is lower than in the non-HIV/AIDS population, 
which may point to an impaired immunoreaction with unreliable detection of Taenia solium 
cysticercosis antibodies [86,87]. The fact of unreliable Taenia solium cysticercosis serodiagnosis 
could present a substantial problem in the HIV/AIDS population with focal neurological signs 
in whom tuberculous meningitis/tuberculoma and toxoplasmosis, two diseases with different 
therapeutic approaches, represent the most important differential diagnoses. 
2.2. Monetary burden of neurocysticercosis in sub-Saharan Africa  
A comprehensive estimate of the monetary burden of cysticercosis in the Taenia solium 
cysticercosis hyperendemic Eastern Cape Province of South Africa indicated the monetary 
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burden per capita to be between US$ 2.6 and US$ 4.8, which is substantial when compared 
to annual health expenditures of US$ 41.3 per capita for people living in poor dwellings in 
that province. The overall monetary burden was calculated to vary from US$ 18.6 million to 
US$ 34.2 million depending on the method used to estimate productivity losses. The 
epilepsy prevalence of the Eastern Cape Province, the proportion of people with epilepsy 
seeking medical care and the proportion of epilepsy cases attributable to NCC as well as the 
proportion of work time lost due to NCC were found to have the most influence on the 
estimated monetary burden [88]. The total societal costs due to Taenia solium cysticercosis in 
the main pig breeding region of West Cameroon (West, Southwest and Northwest 
Provinces) was also recently estimated [89]. Based on an epilepsy prevalence of 3.6%, the 
number of people with NCC-associated epilepsy was estimated at 50 326, representing 1.0% 
of the local population, whereas the number of pigs diagnosed with cysticercosis was 
estimated at 15 961 (based on lingual examination results), which corresponds to 5.6% of the 
local pig population. The total annual costs due to Taenia solium cysticercosis in West 
Cameroon were estimated at € 10.3 million, of which 4.7% were due to losses in pig production 
and 95.3% to direct and indirect losses caused by human Taenia solium cysticercosis. The 
monetary burden per case of human NCC amounted to € 194 and the average number of 
Disability-Adjusted Life Years (DALYs) lost was 9.0 per thousand persons per year which was 
higher than estimates for some other neglected tropical diseases [89]. 
2.3. Staging, pathology and clinical characteristics of neurocysticercosis  
In humans, after the ingestion of Taenia solium eggs, oncospheres hatch and penetrate the 
gut wall. They are transported via the bloodstream and cysticerci form within a few 
weeks/months, mainly in subcutaneous tissue (painless, palpable, cystic lesions), skeletal 
muscle (lesion may not be palpable), the eye and the central nervous system, particularly in 
the brain but also in the spinal cord ([90]; Figure 2). Differences in phenotype of cysticercosis 
between various regions of the world have been described, indicating that the subcutaneous 
form of cysticercosis is most frequent in Asia, least prevalent in Latin America and that 
reports of its occurrence are conflicting in sub-Saharan Africa [67]. Especially cysticercosis of 
the eye and central nervous system are of clinical importance, where cysticerci can cause 
inflammation and/or space-occupying lesions with a mass effect and/or obstruction with 
resulting hydrocephalus. 
In the brain, immature cysticerci appear within 1-4 weeks after the ingestion of eggs (stage 
1). After approximately 1 month, this phase is followed by the maturation of cysticerci, 
which happens with surprisingly little or no inflammation (stage 2). This stage can last for 
more than 10 years and cysticerci survive by disarming host defences. Neurological 
symptoms and/or signs are not usually reported. Stage 3 (2-10 years or more after cysticerci 
maturation) is characterized by an intense host immunoresponse leading to the 
degeneration of cysticerci (granuloma), which may now cause neurological symptoms 
and/or signs [91]. The reasons for cysticerci to eventually be recognized by the host and 
thereby to go from stage 2 to stage 3 have not been understood so far. Antihelminthic 
treatment seems to accelerate this transition, as often the administration of antihelminthic 
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medication causes perifocal oedema surrounding the parasite [62]. In stage 4, the 
inflammatory response has resolved, either without scarring or leaving behind residual 
calcifications ([91]; Figure 2). 
 
Courtesy of Prof. Theodore Nash who has also given permission for reproduction, Laboratory of Parasitic Diseases, 
National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA. 
Figure 2. Cross-section of a human brain showing various stages of neurocysticercosis, including cysts 
showing the scolex (stage 2), granulomas with surrounding inflammation (stage 3) and calcifications 
(stage 4). For more details refer to section 2.4. in the main body of the text. 
NCC can cause a variety of symptoms and signs depending on the number, size, stage and 
location of the pathological changes as well as the host’s immunoresponse and the parasite’s 
genotype, or it can also be clinically asymptomatic. Post-mortem studies have shown that in 
up to 50% of people with NCC the cerebral lesions were asymptomatic [59]. There may be 
single or multiple cysticerci in the brain (intraparenchymal NCC, approximately 80%; Figure 
2) and, in extreme cases, encephalitis (Figure 2) may ensue. Single enhancing 
(intraparenchymal) lesions (SEL) represent a separate entity that has been described mainly 
in patients from the Indian subcontinent. Differential diagnosis is difficult and may 
encompass tuberculoma, toxoplasmosis, brain abscess and tumours, among others. A lesion 
< 2 cm in diameter without gross perifocal oedema and subsequent growth is likely to 
represent a degenerating Taenia solium cysticercus. Patients mainly present with partial 
onset seizure with or without generalisation and have a high risk of seizure recurrence. 
Contrary to India, multiple lesions mainly of the intraparenchymal type seem to prevail in 
people with NCC from Latin America, sub-Saharan Africa and other Asian countries 
although scientific publications on NCC-related neuroimaging from sub-Saharan Africa and 
Asian countries other than India are rare [67,92,93].  
Cysticerci can also occur in the ventricular system and/or the subarachnoid space 
(extraparenchymal NCC, approximately 20%), which is often associated with 
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intraparenchymal NCC. Ventricular disease may cause ependymitis and/or increased 
intracranial pressure. Arachnoiditis, especially in the basal cisterns, which can lead to 
communicating hydrocephalus, vasculitis and/or compression of cerebral vessels, can result 
from subarachnoid disease. Intramedullary cysticerci can be found in the spinal cord, 
causing focal neurological symptoms/signs, and extramedullary cysticerci can cause 
radicular symptoms and/or signs [94].  
If cerebral cysticerci or calcifications are intraparenchymal, epileptic seizures and/or 
epilepsy may ensue [95,96]. During stage 3 of cyst degeneration new-onset acute 
symptomatic epileptic seizures can occur that usually resolve after the inflammation has 
died down, which is very characteristic of this phase. In the case of remaining calcifications, 
recurrent epileptic seizures, i.e. epilepsy, can develop, although fortunately most patients 
remain asymptomatic ([91,97]; see 1.1.). The majority of cysticerci calcify, but cysticerci may 
also become invisible on CT and magnetic resonance imaging (MRI). Although the parasite 
is assumed dead, intermittent flares of oedema around calcifications have been described 
and they seem to be associated with increased seizure activity. The mechanisms of oedema 
occurrence however is not fully understood, but increased antigen accessibility with 
subsequent enhanced immunoresponse have been suggested. Another cause for the 
development of epilepsy after cyst resolution is the development of perilesional gliosis 
around calcifications secondary to prior inflammation [97]. 
A systematic review on the clinical manifestations in people with NCC showed that the 
majority of symptomatic adult cases (78.9%) had epileptic seizures [58]. This may be the 
only presentation, especially in people with single enhancing granulomatous lesions that 
bears a good prognosis compared to infection with multiple cysticerci [92]. Epileptic 
seizures were followed by headaches in 27.7% of people [58]. Headache in people with NCC 
can be acute or chronic, and presents as tension-type or migraine-like episodes [98,99]. 
Headache can also indicate raised intracranial pressure [90]. Furthermore, adults with NCC 
also present with focal neurological signs (11.8%), signs of intracranial hypertension (16.3%), 
meningitic symptoms (5.6%), gait abnormalities (5.6%) and altered mental state/psychiatric 
symptoms (28.1%), among others [58]. Forlenza et al. [100] examined 38 cases with NCC and 
found cognitive decline in 87.5% and psychiatric illness in 65.8% of them, with depression 
and psychosis being the most frequent psychiatric disorders. These findings were 
corroborated by a study from Brazil which showed that cognitive impairment was 
ubiquitous in 40 patients with NCC and that dementia was obvious in 12.5% [101]. A recent 
interesting and well conducted study, although small in sample size, showed that people 
with new-onset epileptic seizures and NCC performed worse on cognitive tests including 
scores for attention, processing speed, learning and memory compared to controls with and 
without epilepsy (people with epilepsy unrelated to NCC and healthy neighbourhood 
controls). However, the difference was only significant for the attention score (people with 
epilepsy and NCC compared to epilepsy controls). Over time (6 month-follow up) people 
with NCC-based epilepsy, who were all treated with albendazole, had significant 
improvement in psychomotor speed and working memory, but there were no significant 
changes in any of the cognitive test scores above, although a general trend for better 
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performance after treatment was visible. Both epilepsy groups were controlled for seizure 
frequency and antiepileptic medication was kept constant during the study period [102]. 
In children with NCC from a series of studies conducted in Latin America, mainly single 
colloidal parenchymal cysts were seen, but heavy infection was also described. 
Calcifications were seen less often and the development of hydrocephalus, and basal 
subarachnoid disease seemed to be rare [83,103,104]. The most frequent clinical presentation 
in children is epileptic seizures followed by headaches and signs of elevated intracranial 
pressures. The only major difference compared to adults was that children portrayed 
relatively little psychiatric symptoms [58]. 
2.4. Diagnosis of neurocysticercosis including information on sub-Saharan 
Africa 
A suspected diagnosis of NCC (e.g. epileptic seizures in a patient from an area endemic for 
Taenia solium cysticercosis) should be confirmed with a combination of neuroimaging and 
serology, if possible. On neuroimaging cysts, granulomas and/or calcifications will support 
the clinically based suspicion of NCC. However, these lesions may also be caused by other 
pathogens and pathological processes and therefore combination with Taenia solium 
cysticercosis serology is highly desirable. Both, neuroimaging and Taenia solium cysticercosis 
serology are often not available in resource-poor settings, but routine cerebrospinal fluid 
analysis may point the direction and can be obtained from patients without major 
impairment of consciousness. Cerebrospinal fluid analysis in NCC very often is 
unremarkable, but it may also show signs of parasitic disease, especially in multicystic 
disease and intraventricular/subarachnoid forms of NCC, including slightly elevated cell 
count (usually not exceeding 100 cells/µl, demonstrating mononuclear pleocytosis and 
eosinophilia) and increased protein levels in the range of 50 to 300 mg/dl. Glucose levels are 
usually normal [105].  
Today a wide array of serological tests for Taenia solium cysticercosis exist such as the 
antigen/antibody enzyme-linked immunosorbent assay (ELISA) and immunoblots which 
can be performed in serum and/or cerebrospinal fluid of suspected cases [90,106-111]. 
However, a positive test only indicates cysticercosis but not necessarily NCC, and the 
sensitivity and specificity for current infection with Taenia solium cysticercus and prior 
exposure to the parasite can vary considerably according to the test used [106, 108, 112]. In 
addition, polymerase chain reaction (PCR) methods for the diagnosis of Taenia solium 
cysticercosis are under development, but so far are not part of routine diagnosis due to 
varying levels of sensitivities and specificities [113,114]. Also, these techniques, with high-
cost equipment and need for regular maintenance may not be suitable for countries of sub-
Saharan Africa. 
When it comes to the availability of Taenia solium cysticercosis serological tests in sub-
Saharan Africa the information is scarce and relies on personal communication. I therefore 
suggest that one of the tasks of the next Cysticercosis Working Group in Eastern and 
Southern Africa (CWGESA) meeting should be the establishment of an accurate list of Taenia 
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solium cysticercosis immunodiagnostic tests available in countries of sub-Saharan Africa. 
The information I have got so far, even after communicating with various stakeholders, is 
not much different form the information published in Winkler et al. [110] and therefore 
would need updating by talking to reference people of the individual countries. In 
summary, in Mozambique and South Africa Taenia solium cysticercosis antibody-ELISA has 
been available for some years (personal communication with Dr Lee Willingham, WHO, 
Geneva, Switzerland). My own cysticercosis project in collaboration with the Department of 
Infectious Disease and Tropical Medicine of the University of Munich and funded by the 
German Research Foundation is currently transferring capacity for Taenia solium 
cysticercosis antibody-ELISA to the CWGESA Regional Reference Centre for 
Immunodiagnosis of Taenia solium Infections at the University of Zambia, to Gulu 
University of Uganda and to Muhimbili University of Health and Allied Sciences of 
Tanzania. There are also plans to transfer the new T24 recombinant-based antibody-ELISA 
test developed by the U.S. Centers for Disease Control and Prevention to Zambia, 
Mozambique and Madagascar (personal communication with Dr Lee Willingham, WHO, 
Geneva, Switzerland) and according to the latest information training of personnel has 
started (personal communication with Dr Patricia Wilkins, U.S. Centers for Disease Control 
and Prevention, Atlanta, USA). Diagnostic possibilities for Taenia solium cysticercosis in terms 
of immunoblot currently do not exist in countries of sub-Saharan Africa. A Taenia solium 
cysticercosis antigen-ELISA has been performed over the last years in Zambia at the CWGESA 
Regional Reference Centre for Immunodiagnosis of Taenia solium Infections at the University 
of Zambia. Member countries of the CWGESA send samples for antigen-ELISA testing to this 
reference laboratory. Recently, antigen-ELISA facilities have also been established in 
Mozambique, Madagascar, South Africa, Burkina Faso and Cameroon (personal 
communication with Dr Lee Willingham, WHO, Geneva, Switzerland). Confirmation whether 
these tests are still functional has not been obtained from the individual countries, but could be 
included into the working schedule of the next CWGESA meeting. 
Although positive serological and/or DNA-based tests may give the first indication, the gold 
standard of NCC diagnosis is neuroimaging, including CT and/or MRI, both of which are 
generally not available in sub-Saharan Africa. In neuroimaging, only a lesion showing the 
scolex (= head of the parasite) is classified as a definite NCC lesion and considered 
pathognomonic [90,106,107,109]. Active NCC is defined as the presence of any cystic lesions 
(with or without scolex) or lesions with ring enhancement. In contrast, parenchymal 
calcifications are classified as inactive [95,97]. 
Cysts are best visualized on MRI, whereas CT is the imaging of choice for calcifications. Cyst 
fluid shows the same signal than cerebrospinal fluid and is hypointense (dark signal) on T1-
weighted images as well as fluid attenuated inversion recovery (FLAIR) sequences and 
hyperintense (bright) on T2-weighted images. In the vesicular stage of NCC, there is no 
surrounding oedema. Cysts are usually 1-2 cm in diameter and the scoleces inside the cysts 
1-2 mm. The latter is isointense relative to brain parenchyma (Figure 3a). During the 
degenerative process with thickening of the cyst wall, increased protein content of the cyst 
fluid and surrounding inflammatory signs, the signal intensity of the cyst fluid is higher 
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than that of cerebrospinal fluid on T1-weighted images, but still hypointense compared to 
parenchyma, and hyperintense on T2-weighted images (colloid vesicular stage), whereas the 
cyst wall is hyperintense on T1- and hypointense on T2-weighted sequences. As the 
degeneration goes on with proliferation and retraction of the cyst wall and reabsorption of 
the fluid (granular nodular stage) the granuloma becomes isointense and eventually 
hyperintense on T1- and hypointense on T2-weighted images. Ring-enhancement or total 
enhancement of the degenerative cysticerci after application of contrast indicates 
inflammation and subsequent disruption of the blood-brain barrier with leakage of plasma 
into cerebral tissue and is best visualized on T1-weighted images (Figure 3b). Perifocal 
oedema is best seen on FLAIR sequences (bright signal) and T2-weighted images (less bright 
signal). Calcifications (nodular calcified stage) often go unnoticed on MRI or may appear as 
small iso- or hypointense lesions on T1- and T2-weighted images [115]. Subarachnoid NCC 
shows multiple cystic masses in the basal cisterns or Sylvian fissure, among other locations. 
The masses may be lobulated and compress adjacent structures. Signal intensity usually 
compares with that of cerebrospinal fluid on all magnetic resonance sequences and is best 
seen as dark signal in T1-weighted and FLAIR images (Figure 3c). Ventricular NCC shows 
best on T1-weighted sequences, because on T2-weighted images the high signal intensity of 
the cyst fluid is indistinguishable from that of the cerebrospinal fluid (refer to chapter on 
extraparenchymal NCC) [115]. On CT scan cysts are hypodense (Figure 4a) and granuloma 
may be isodense to the parenchyma and only be seen after administration of contrast 
(Figure 4b). Calcifications are hyperdense (Figure 4c). Extraparenchymal NCC can easily be 
missed on CT, especially the ventricular form.  
 
All pictures are courtesy of Prof. Hector H. Garcia, Department of Microbiology, School of Sciences, and Director 
Center for Global Health - Tumbes, Universidad Peruana Cayetano Heredia, Lima, Peru. 
Figure 3. a-c): magnetic resonance images of neurocysticercosis lesions; 3a) axial T1-weighted image 
showing a pathognomonic cyst with scolex (approximate diameter of 1 cm) in the right occipital lobe; 
3b) coronal T1-weighted contrast enhanced image, showing a cystic lesion with an enhancing rim in the 
left parietal lobe; 3c) sagittal T1-weighted image showing extraparenchymal subarachnoid cysticercosis 
with multiple, lobulated cystic lesions predominantly in the subarachnoid space (prepontine, 
suprasellar cistern and cisterna ambiens) as well as probable intraventricular lesions with potential 
dilation of the 4th ventricle. 
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Permission for reproduction has been obtained from SpringerWienNewYork. The pictures were originally published 
in Winkler AS, Willingham L 3rd, Sikasunge CS, Schmutzhard E. Epilepsy and neurocysticercosis in sub-Saharan 
Africa. Middle European Journal of Medicine 2009; 121 (suppl 3): 3-12. 
Figure 4. a-c) axial computed tomography images of various stages of neurocysticercosis lesions; 4a) 
pathognomonic subcortical cyst left showing the scolex with a close-by calcification; calcified 
subcortical cyst right with perifocal/perilesional oedema; calcification in the left temporal muscle; 4b) 
“ring enhancing lesion” due to a degenerating subcortical cyst in the right occipital lobe; 4c) several 
scattered intraparenchymal calcifications most likely in the context of neurocysticercosis.  
In a resource-rich setting the combination of MRI and CT makes a lot of sense to neither 
miss cystic lesions or granulomas nor calcifications. Combination of neuroimaging and 
immunodiagnostic test is strongly advised and their results together with clinical, 
pathological and epidemiological criteria as well as response to treatment with 
antihelminthic drugs are summarized in the diagnostic criteria for NCC suggested by Del 
Brutto et al. [107,109,116]. If neither immunodiagnostic tools nor neuroimaging are 
available, extirpation of subcutaneous nodules and a thorough ophthalmological 
examination may support the suspected diagnosis [107,109,116]. Due to an emphasis on 
neuroimaging and serological tests, the Del Brutto criteria seem to be rather impractical for 
its use in resource-poor settings and may need adjustment to suit local circumstances. 
2.5. Treatment of neurocysticercosis with a focus on sub-Saharan Africa 
In the treatment of NCC, symptomatic (steroids, antiepileptic medication, analgesics) and 
potentially curative treatment (antihelminthic medications) has to be differentiated. 
Indication and contraindication for antihelminthic treatment as outlined below must be 
observed. Neuroimaging is mandatory to start treatment with antihelminthic drugs and 
therefore antihelminthic treatment is not indicated in most patients from sub-Saharan Africa 
(except South Africa), where neuroimaging is absent. If there is any doubt as to the 
appropriateness of antihelminthic treatment, symptomatic treatment should be favoured. In 
addition, the treatment approach in acutely symptomatic and life-threatening disease is 
different form the more chronically symptomatic condition (see 2.5.1.). 
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2.5.1. Antihelminthic and/or anti-oedematous treatment  
Currently, there are no standard treatment guidelines for NCC; therefore treatment has to be 
tailored to the individual case. Only active disease needs treatment with antihelminthic drugs 
and/or steroids. Dosages and the duration of treatment can be highly variable and mainly 
depend on the number, size, location and developmental stage of the cysts, their surrounding 
inflammatory oedema, clinical symptoms/signs (their acuteness and severity) as well as 
potential risk factors of treatment. On the one hand, care needs to be taken not to “over-treat” 
as the administration of antihelminthic drugs can cause cerebral oedema and worsen 
symptoms and, on the other hand, one has to be prepared to extend treatment for some 
months as the penetration of drugs into cysts can be poor. The follow-up of patients has to be 
ensured, ideally with neuroimaging, but this may not be available in resource-poor settings 
[90,95,117]. Although treatment has to be flexible, there are some rules of thumb that should be 
followed. The administration of antihelminthic drugs may elicit or increase pre-existing 
cerebral oedema and therefore is contraindicated in cases with increased intracranial pressure, 
subarachnoidal NCC in close proximity to blood vessels and NCC encephalitis (Figure 2). In 
these conditions, steroids should be administered alone and may later be combined with 
antihelminthic drugs. In intraparenchymal active NCC without signs of increased intracranial 
pressure, steroids should be administered simultaneously with antihelminthic treatment, at 
least for the first week. The antihelminthic drug of choice is albendazole, which unfortunately 
is not often available in sub-Saharan Africa. The suggested dose is 15 mg/kg per day for 8-15 
days. Praziquantel can also be used to treat NCC, although it is not as effective as albendazole 
[118], but it can be found in most sub-Saharan countries. Its recommended dose is 50 mg/kg 
per day for 15-30 days [90,94,117]. Metabolism of praziquantel and albendazole is increased 
with simultaneous usage of antiepileptic drugs, in particular phenytoin and carbamazepine, 
and the levels of praziquantel are reduced when the drug is administered together with 
steroids. Co-administration with cimetidine may increase the bioavailability of praziquantel 
[90,94]. Alternatively the dose of praziquantel may be increased or its course shortened and 
repeated. Also, in resource-poor settings, patients may not be particularly compliant with 
treatment. The best solution would be to keep the patient in hospital for the time of treatment, 
but due to financial expenses the patient may not agree. To minimise costs an elegant solution 
may be a high-dose short-term treatment with 100 mg/kg praziquantel in three divided doses 
every two hours followed by corticosteroids. This treatment regimen has been demonstrated 
to be successful in single cyst disease, but unfortunately efficacy could not be demonstrated in 
patients with multiple cysts, which is the phenotype that prevails in sub-Saharan Africa 
[67,119,120]. Even with normal dosage and course of treatment cure rates with antihelminthic 
drugs in general seem to be low. In untreated patients, 40% of cysts are cleared and in treated 
patients 60% of cysts disappear after one course of treatment. Furthermore, rebound 
inflammation may occur after abrupt withdrawal of antihelminthic medication and/or steroids 
and may be due to overcompensation of the immune system after removal of treatment with 
anti-inflammatory medication [117]. 
Steroids should be initiated together with antihelminthic drugs in intraparenchymal disease 
and ideally should be administered for as long as the patient is symptomatic (e.g. chronic 
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progressive headache, acute symptomatic epileptic seizures) but at least for the first days 
antihelminthic treatment is given. So far steroid doses in the treatment of NCC have not 
been standardized [121]. Prednisone is recommended at a dosage of 1 mg/kg per day either 
p.o. or i.v.. Alternatively, dexamethasone can be used at 12-24 mg/d, maximum of 30 
mg/day, p.o. or i.v.. Metabolism of both drugs may be increased by antiepileptic medication 
[90,94]. Steroids are used in all condition where cerebral oedema is present or may develop. 
To date there are only four controlled trials of the use of steroids in NCC and all of them 
were conducted in single enhancing granulomatous lesions (see 2.4.). Treatment regimens 
consisted of prednisolone 1 mg/kg for 10 days with a 4-day taper with and without 
antiepileptic treatment, prednisolone 1 mg/kg for 7 days with a 3-day taper without 
antiepileptic treatment and methylprednisolone 1 g/1.72 m2 for 5 days without antiepileptic 
treatment. All studies showed a decrease in epileptic seizures and three showed a significant 
clearance of cysts on CT [122-125]. 
In summary, only confirmed active intraparenchymal and symptomatic (e.g. epileptic 
seizures) disease requires treatment with triple therapy, i.e. antihelminthic medication, 
steroids and antiepileptic medication. For antiepileptic treatment see 2.6.2. Once the parasite 
has gone into the transitional stage, antihelminthic drugs may no longer be needed as the 
parasite is already attacked and destroyed by the host. Current advice is that the 
symptomatic patient of the transitional stage should be maintained on symptomatic 
treatment only, i.e. steroids and antiepileptic medication [126]. There is however some 
controversy over the topic of treatment of the transitional stage and new results are 
expected shortly (personal communication with Prof. Hector H. Garcia, Universidad 
Peruana Cayetano Heredia, Lima, Peru). In inactive symptomatic disease the patient should 
receive antiepileptic mediation only if seizures are present. If perilesional oedema is 
obvious, steroids may be beneficial, although there are only anecdotal reports [121]. 
Treatment of extraparenchymal disease is much more tedious than that of intraparenchymal 
disease, and in most cases requires lengthy treatment regimens with antihelminthic 
medication and steroids or operative procedure if cysts are located in the ventricles [117]. 
For more details refer to the chapter of extraparenchymal NCC…  
Furthermore, treatment of affected individuals only represents one facet in the multifaceted 
approach towards the eradication of NCC. Another important step is the prevention 
(reducing the number of free-roaming pigs, the vaccination of pigs) and treatment of porcine 
cysticercosis as well as the treatment of Taenia solium taeniosis (human tapeworm infection; 
[47,67,127,128]). In addition, increasing hygienic standards in affected communities, meat 
inspections, educating farmers and health education within communities should be top 
priorities in the fight against NCC. For more details refer to the chapter of ... 
2.5.2. Antiepileptic treatment 
Antiepileptic treatment should be initiated if seizure activity is recurrent, irrespective of 
whether epileptic seizures occur within the setting of stage-3 symptomatic cysts or stage-4 
calcifications after clearance of the parasite (see 2.2.). According to the latest guidelines of 
the International League Against Epilepsy [129], treatment should be initiated after the 
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first epileptic seizure if seizures are caused by an underlying lesion. In resource-poor 
settings without access to neuroimaging, an underlying lesion in the context of NCC can 
only be assumed if certain factors such as neurological signs on examination or a contact 
history with a tapeworm carrier or pigs are present. In some hospitals, 
electroencephalography may be available and focal activities on electroencephalograms 
may help decide when to start treatment.  
Antiepileptic medication is limited in sub-Saharan Africa. The mainstay of antiepileptic 
treatment is phenobarbitone, although phenytoin and carbamazepine can also be found in 
rural African hospitals, but their supply is often erratic. Valproate is stocked only 
occasionally, and most times is not delivered through the national pharmacies, but relies on 
private donations. Dosing and potential side effects of antiepileptic medication available in 
sub-Saharan Africa are given in Table 1.  
 
Antiepileptic 
medication 
(indication) 
Starting dose Titration  
(~usual adult 
maintenance 
dose) 
Side effects (list non-
exhaustive) 
Route of 
administration 
Phenobarbitone 
(all forms of 
epilepsy; may 
be tried in 
atypical 
absences, atonic 
and tonic 
seizures) 
1. 30 mg p.o.
2. (rapid) 50 mg i.v., s.c. or  
i.m. every 6 h diluted 1:10 
with inj. water 
3. (status) 20 mg/kg i.v. 
diluted 1:10 with inj. water 
(start with 200-400 mg) 
(maximum rate: 100 
mg/min) 
30 mg p.o. 
every 3 days 
(long half-life)
(~60-180 
mg/day) 
neurological/psychiatric:
fatigue, drowsiness, lethargy, 
pronounced cognitive decline, 
learning disabilities, 
headaches, ataxia, nystagmus, 
dysarthria, depression, 
agitation, aggression, 
hyperkinesia (children), 
confusion (elderly); other: 
megaloblastic anaemia (may 
be treated with folic acid**), 
constipation, rickets and 
osteomalacia (vitamin D 
deficiency**), impotence; 
vitamin K deficiency** and 
withdrawal seizures in new-
borns; teratogenicity 
rapid titration in status: 
respiratory depression
oral, i.v., s.c., 
i.m. 
Carbamazepine 
(partial (simple 
and complex) 
and secondary 
generalised 
tonic-clonic 
seizures; some 
primary 
generalised 
seizures; not in 
absences and 
myoclonic 
seizures) 
200 mg p.o. 200 mg p.o.
every 3-5 days
(~800-2000 
mg/day) 
skin: from transient 
erythematous rash*** 
(frequent) to Stevens-Johnson 
syndrome, photosensitivity 
lupus erythematosus; blood: 
leucopenia, 
thrombocytopenia, 
agranulocytosis, aplastic 
anaemia; cardiovascular: 
conduction disturbances, 
thromboembolism; gastro-
intestinal: nausea, vomiting, 
cholestatic jaundice, hepatitis, 
constipation, diarrhoea, 
oral 
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Antiepileptic 
medication 
(indication) 
Starting dose Titration  
(~usual adult 
maintenance 
dose) 
Side effects (list non-
exhaustive) 
Route of 
administration 
anorexia; genito-urinary: renal 
failure, proteinuria, 
impotence; 
neurological/psychiatric: 
dizziness, drowsiness, 
headache, ataxia, confusion, 
agitation, visual disturbances 
(double vision often 
associated with peak plasma 
levels), dyskinesia, 
paraesthesia, depression, 
activation of psychosis; other: 
alopecia, arthralgia, fever, 
lymph node enlargement, 
gynaecomastia, galactorrhoea, 
pulmonary hypersensitivity, 
hyponatraemia, oedema, 
osteomalacia; teratogenicity;
Phenytoin (all 
forms of 
epilepsy except 
absence seizures 
and myoclonic 
seizures) 
1. 300 mg p.o.
2. (rapid) 600 mg p.o. for 3 
days 
3. (status) 1.5 g  i.v. diluted 
1:10 with inj. water (first 250 
mg as bolus over 10 
minutes, next 500 mg in 0.5 
to 6 hours, next 750 mg in 1-
24 hours according to clinic)
(maximum rate: 20 mg/min)
25-50 mg p.o.
per day 
(~200-500 
mg/day*) 
skin and gum: gingival
hypertrophy and tenderness, 
coarse facies, hirsutism, acne, 
rash***, lupus erythematosus, 
Stevens-Johnson syndrome, 
toxic epidermal necrolysis; 
blood: megaloblastic anaemia 
(may be treated with folic 
acid**) leucopenia, 
thrombocytopenia, 
agranulocytosis, aplastic 
anaemia; gastro-intestinal: 
nausea, vomiting, hepatitis, 
liver failure; 
neurological/psychiatric: 
vertigo, double vision, 
nystagmus, tremor, confusion, 
dizziness, headache, insomnia 
dyskinesia; ataxia, slurred 
speech, nystagmus and 
blurred vision (are signs of 
overdosage); peripheral 
neuropathy, irreversible 
cerebellar atrophy; other: 
fever, polyarthritis, 
lymphadenopathy, rickets 
and osteomalacia (lowered 
plasma calcium 
concentration); teratogenicity;
rapid titration in status: 
cardiac dysrhythmias, 
hypotonia 
oral, i.v. 
(beware of 
phlebitis) 
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Antiepileptic 
medication 
(indication) 
Starting dose Titration  
(~usual adult 
maintenance 
dose) 
Side effects (list non-
exhaustive) 
Route of 
administration 
Valproate (all 
forms of 
epilepsy; drug 
of choice in 
primary 
generalised 
epilepsy, 
generalised 
absences and 
myoclonic 
seizures; may be 
tried in atypical 
absences, atonic 
and tonic 
seizures, Salaam 
attacks; has got 
similar efficacy 
to that of 
phenytoin and 
carbamazepine 
in partial 
epilepsy) 
1. 600 mg p.o. 
2. (status) 3.6 g  i.v. diluted 
approx. 1:10 with inj. water 
(first 1.2 g as bolus over 10 
minutes, second 1.2 g as 
bolus over 10 minutes, next 
1.2 g in 12-24 hours 
according to clinic) 
(maximum rate: 100-200 
mg/min) 
150-300 mg p.o. 
every 3 days 
(~ 900-3000 
mg/d) 
skin: rash, toxic epidermal 
necrolysis, Stevens-Johnson 
syndrome, vasculitis, 
hirsutism, acne; 
blood: thrombocytopenia, 
inhibition of platelet 
aggregation, leucopenia, 
pancytopenia, red cell 
hypoplasia, fibrinogen 
reduction; 
gastro-intestinal: nausea, 
vomiting, increased appetite 
and weight gain, impaired 
hepatic function leading 
rarely to fatal hepatic 
failure****, rarely 
pancreatitis*****, 
hyperammonaemia; 
neurological/psychiatric: 
ataxia, tremor, dizziness, 
sedation (rarely lethargy and 
confusion associated with too 
high an initial dose), 
increased alertness, 
occasionally aggression, 
hyperactivity and 
behavioural disturbances, 
extrapyramidal symptoms, 
dementia, acute valproate-
induced 
encephalopathy******; 
other: irregular periods, 
amenorrhoea, 
gynaecomastia, hearing loss, 
Fanconi’s syndrome, fatigue, 
hair loss, oedema   
oral, i.v. 
*has a narrow therapeutic index and the relationship between dose and plasma concentration is non-linear; small 
dosage increases in some patients may produce large rise in plasma concentration with acute toxic side-effects; a few 
missed doses or a small change in drug absorption may result in a marked change in plasma concentration. 
**consider vitamin administration together with antiepileptic medication 
***discontinue; if mild re-introduce cautiously, but discontinue immediately if recurrence 
****withdraw treatment immediately if vomiting, anorexia, jaundice or/and loss of seizure control occurs 
*****measure plasma amylase in acute abdominal pain 
******withdraw treatment immediately if within the first week of starting medication impairment of consciousness, 
increased seizure frequency, dysarthria and/or, asterixis  occurs 
Table 1. Antiepileptic medication available in sub-Saharan Africa: indication, drug loading, titration 
and maintenance doses as well as side effects (in the order of their availability; adjusted from [67]) 
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Epileptic seizures in the context of NCC are of the secondary generalized type, but very 
often clinical examination does not reveal neurological signs. Therefore, in practice, it is 
difficult to differentiate epileptic seizure due to NCC from other types of seizures. Given the 
limited supply of medication, the most appropriate antiepileptic medication for seizures 
caused by NCC would be carbamazepine which is effective for partial seizures and 
secondary generalised seizures. It has generally fewer side-effects than phenytoin or the 
barbiturates, but reversible blurring of vision, dizziness and unsteadiness are dose-related 
and may be dose-limiting (Table 1). If carbamazepine is absent or if it is not tolerated, 
phenobarbitone and phenytoin can also be administered. However side effects may limit 
their use (Table 1). Therefore, if in a patient with normal neurological examination 
additional tests such as a positive result on Taenia solium cysticercosis antigen serology 
and/or neuroimaging indicate a focal start of the seizure, the patient should be started on 
carbamazepine first. As most people with epilepsy in sub-Saharan Africa do not have access 
to these investigations, treatment has to be started according to the suspected origin of the 
seizures and based on the experience of the involved physician. Also, phenobarbitone, 
despite its unpleasant side effect profile, has been shown to be a highly effective drug when 
it comes to seizure control. Surprisingly, many adults tolerate it fairly well, but its use has to be 
very restrictive in children and women of child bearing age because of possible cognitive 
decline and withdrawal seizures in the new-born, respectively (Table 1). A recent study from a 
Taenia solium cysticercosis endemic area of northern Tanzania showed that compliant people 
with epilepsy and NCC were well controlled on antiepileptic monotherapy with a trend 
towards better seizure control under carbamazepine compared to phenobarbitone. However, 
sample size in the groups was small and a final conclusion as to which of the two drugs leads 
to better seizure control in people with epilepsy and NCC cannot be drawn with certainty [74]. 
In addition to choosing the right antiepileptic medication, communication with the patients 
and their families is vital. The treatment gap for people with epilepsy in sub-Saharan Africa 
is substantial and it is most important to take its causative factors into consideration when 
counselling people with epilepsy (see 1.4.). It is also mandatory that patients who are started 
on antiepileptic medication and their families are informed about potentially ensuing side 
effects as well as the temporary nature of some of them in order to enhance compliance with 
medication. Follow-up appointments in short interval are advisable in the early phase of 
antiepileptic treatment. When informing patients about their treatment it has to be 
emphasized that withdrawal seizures can occur when stopping antiepileptic medication 
abruptly and that once their seizures abate the medication still has to be continued until the 
physician decides to withdraw the medication. There are no guidelines as to withdrawal of 
antiepileptic mediation in the context of NCC and therefore this has to be decided on a case-
to-case basis. Usually withdrawal is considered when the epilepsy is in remission, i.e. the 
patient has to be seizure free for two years, although one year may be considered enough in 
resource-poor settings. Predictors for remaining seizure-free after withdrawal of 
antiepileptic medication seem to be normal neurological examination and use of 
carbamazepine prior to withdrawal [130], indicating outcome after drug withdrawal may be 
favourable in people with epilepsy and NCC. However, longitudinal studies on withdrawal 
of antiepileptic medication in people with epilepsy and NCC in sub-Saharan Africa have not 
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been performed so far, but would definitely be needed to be able to develop guidelines on 
withdrawal of antiepileptic medication in this population. 
2.5.3. Treatment in the absence of neuroimaging 
The majority of patients in resource-poor settings have neither got access to neuroimaging 
nor to Taenia solium cysticercosis immunodiagnostic tests. Although positive results on 
Taenia solium cysticercosis antigen-ELISA may indicate active disease [131], treatment with 
antihelminthic medication must not be initiated on the basis of serology alone as cyst stage 
and presence of oedema cannot be estimated. Oedema can potentially be aggravated by 
antihelminthic medication resulting in deterioration of the patient’s condition and, in the 
worst case, death may ensue caused by cerebral herniation leading to compression of the 
brainstem with severe compromise of vital functions. Therefore, I strongly suggest that in 
the absence of neuroimaging patients should be treated symptomatically only, i.e. anti-pain 
medication and antiepileptic drugs (see 2.5.2.).  
The administration of steroids as symptomatic treatment in patients with signs and 
symptoms of increased intracranial pressure, such as chronic progressive headache in the 
context of suspected but not imaging-confirmed NCC, is debatable and has to be decided on 
an individual basis. A classical scenario where steroid administration may be advisable is in 
patients with acute symptomatic seizures who come from a Taenia solium cysticercosis 
endemic area. High doses of steroids may be started in these patients and tapered once 
symptoms abate. At the same time antiepileptic medication should be started on which the 
patient will be maintained until fit for withdrawal (see 2.5.2.). In this context, it is however 
crucial to exclude the most important differential diagnoses such as cerebral malaria, 
bacterial and tuberculous meningitis as well as encephalitis, among others, for which a 
spinal tap is necessary. The result of cerebrospinal fluid analysis is usually unequivocal for 
bacterial meningitis and in that case steroids are not to be started without antibacterial 
treatment. The result of cerebrospinal fluid analysis in tuberculous meningitis and viral 
encephalitis may be similar to that in NCC (although most patients with intraparenchymal 
NCC show normal results on cerebrospinal fluid; see 2.4.) with an unspecific medium 
increase in cell count and no major other obvious abnormalities, especially in a resource-
poor setting where protein and glucose often are not measured. The eosinophils may be 
elevated in NCC, but this is not mandatory. Therefore differential diagnosis may prove 
difficult, but a trial of steroids will not harm patients with tuberculous meningitis or viral 
encephalitis as brain oedema may be present and administration of steroids to these patients 
may actually improve their symptoms [132,133].  
Even after satisfactory symptomatic treatment the question remains whether withholding 
antihelminthic treatment in patients with NCC will have disadvantages in terms of cyst 
clearance or seizure control. Results are controversial. Garcia et al. showed that treatment 
with albendazole in addition to antiepileptic medication significantly cleared the parasite 
and reduced seizure frequency, especially those with generalisation, when compared to the 
control group that received antiepileptic medication only [134]. In contrast, in another study 
the same combination of albendazole and antiepileptic treatment in people with NCC was 
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not superior to therapy with antiepileptic drugs alone. The combination treatment led to 
increased hospital admission, increased seizure frequency, more cases of encephalopathy 
and deaths. A greater proportion of lesions calcified compared to the group that was treated 
with antiepileptic drugs alone, in which more lesions resolved completely [135].  
In summary, treatment of NCC in the absence of neuroimaging has to be decided on an 
individual basis and depends on clinical symptoms and/or signs, whether acute or chronic, 
and on the physician’s experience as well as local practice. Most patients with NCC can be 
maintained on antiepileptic medication alone, but steroid application may be considered in 
the severely ill patient bearing in mind the implication of potential differential diagnoses. 
3. Conclusions and outlook 
This chapter demonstrates clearly the importance of epileptic seizures/epilepsy and NCC for 
sub-Saharan Africa in terms of prevalence and burden of each of the two disorders, but it 
also emphasizes NCC as an important cause of acute symptomatic seizures and secondary 
epilepsy in many African countries. Taenia solium cysticercosis is a potentially eradicable 
disease and successful implementation of treatment of human taeniosis and porcine 
cysticercosis (please refer to other chapters in the book) as well as enforcement of hygienic 
measure, such as building of latrines and hand washing after toilet use, among others, may 
prevent many cases of epileptic seizures/epilepsy and therefore reduce individual suffering 
as well as socioeconomic losses to African societies. Although eradication of the disease has 
to be the ultimate aim, treatment of affected individuals for now should be in the forefront 
of activities of African physicians who attend to people with epileptic seizures/epilepsy. I 
have suggested how people with epileptic seizures/epilepsy and/or NCC in resource-poor 
settings should be approached, but want to emphasize that this is my personal 
opinion/experience based on many years of work as a trained neurologist in sub-Saharan 
Africa. Conveying my own opinion in this chapter my aim was to stimulate discussion 
across disciplines and nations. Hopefully national and international stakeholders, such as 
the ministries of health of African countries and The World Health Organization, have by 
now become aware that NCC and the ensuing epilepsy in sub-Saharan African represent a 
“silent epidemic”. Affected people deserve standardized treatment maximizing its benefits 
but at the same time minimizing its drawbacks. In that sense I am hopeful that in the near 
future guidelines on how to treat people with epilepsy and/or NCC will be decided by an 
expert-led commission and enforced as standard of care in sub-Saharan countries by the 
respective national and internal stakeholders. 
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